Despite significant research progress, critical gaps remain
Patients taking Wegovy alongside: Sulphonylureas (e.g., gliclazide, glimepiride) these stimulate insulin release independent of glucose levels Insulin therapy exogenous insulin administration can cause hypoglycaemia regardless of endogenous glucose regulation Meglitinides (e.g., repaglinide) short-acting insulin secretagogues When GLP-1 receptor agonists are combined with these medications, the risk of hypoglycaemia increases substantially
Treating Multiple Conditions: Some people take topiramate for chronic migraines
Serum antioxidant vitamins and risk of cataract
Thank you to our R&D colleagues at Pfizer, our partners at Astellas and Merck, and above all, the people living with bladder cancer and their families who took part in the EV-304 trial and made this possible
As Novo Nordisk boosts Wegovy, Ozempic AD spend, analysis finds a rising tide lifts all boats for diabetes, weight-loss drugs